Gsk Plc ADR
(NY:
GSK
)
38.82
+0.45 (+1.17%)
Official Closing Price
Updated: 4:10 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gsk Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
October 04, 2024
The U.S. government collaborates with GSK, Sanofi, and CSL to enhance bird flu vaccine production. This initiative aims to increase vaccine readiness to 10 million doses by early 2025 amid rising H5...
Via
Benzinga
Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected
October 03, 2024
Guidance for the second cycle of Medicare drug price negotiations has expectations high for significant savings by 2026.
Via
Benzinga
Pfizer Divests $3.3B Stake In Sensodyne Toothpaste And Panadol Painkiller Maker Haleon
October 01, 2024
Pfizer has divested a $3.3 billion stake in Haleon, reducing its holding in the British consumer healthcare company.
Via
Benzinga
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
September 25, 2024
Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms are bidding for the unit, with the spinoff expected by Q4 2024. Banks...
Via
Benzinga
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
July 29, 2024
The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
September 18, 2024
The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial results. The drug showed similar remission rates to GSK's Nucala.
Via
Benzinga
Exposures
Product Safety
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
September 18, 2024
GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The study showed a non-inferior immune response and good safety profiles. The...
Via
Benzinga
Exposures
Product Safety
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
September 16, 2024
Nuvalent and Iteos delivered promising updates in their lung cancer studies. But three patients died in one test.
Via
Investor's Business Daily
Topics
Death
Exposures
Death
Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day
September 13, 2024
The company offered a series of updates that shook shares on Thursday. The selloff continued on Friday.
Via
Investor's Business Daily
GSK Reveals 'Positive' Data From Mid-Stage Study Of Seasonal Influenza mRNA Vaccine
September 12, 2024
GSK announced positive phase 2 trial results for its mRNA seasonal flu vaccine, showing strong immune.
Via
Benzinga
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
September 11, 2024
GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in clinical trials. Moderna and Pfizer's partner BioNTech are still developing HSV...
Via
Benzinga
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
September 06, 2024
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.
Via
Benzinga
Exposures
Product Safety
GSK's Asthma Drug Meets Main Goal In Phase 3 Study In Patients With Smoker's Lungs, Prepares Competition With Amgen/AstraZeneca's Drug
September 06, 2024
GSK's Phase 3 MATINEE trial of Nucala in COPD met the primary endpoint, reducing exacerbations significantly over 104 weeks.
Via
Benzinga
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
August 23, 2024
Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite concerns, experts predict limited financial impact on companies like Pfizer,...
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
August 19, 2024
Via
Benzinga
Florida Ruling Upholds GSK's Stance On Once Popular Heart Burn Drug Zantac Not Being Associated With Cancer Risk
August 16, 2024
A Florida State Court sided with GSK, dismissing expert testimonies that linked ranitidine to prostate cancer, reflecting a broader scientific consensus that there is no consistent evidence supporting...
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
August 15, 2024
Via
Benzinga
New European Regulations Could Hinder Rare Disease Treatments, Pharma Industry Raises Concerns Over Stricter Clinical Trial Rules
August 13, 2024
Pharmaceutical companies, researchers, and patient groups are voicing concerns over new EU regulations that could hinder rare disease treatment development by imposing stricter guidelines on medical...
Via
Benzinga
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
August 12, 2024
Via
Benzinga
Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again.
August 05, 2024
Moderna sustained a rare downgrade on Monday following its guidance cut for the year.
Via
Investor's Business Daily
Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer
August 02, 2024
Moderna cuts its 2024 sales forecast due to weaker demand for COVID-19 vaccines. Sales now expected between $3B-$3.5B, down from $4B. Analysts adjust price targets, citing competitive pressures from...
Via
Benzinga
Exposures
COVID-19
British Pharma Giant GSK's Blockbuster Shingles And Respiratory Syncytial Virus Vaccine Q2 Sales Miss Expectations, Cuts Annual Vaccine Revenue Guidance
July 31, 2024
GSK reported Q2 sales of $9.95 billion, beating estimates of $9.66 billion. Specialty Medicine sales rose 20%, driven by strong HIV, Respiratory/Immunology, and Oncology performance. Core EPS of $1.10...
Via
Benzinga
Topics
Earnings
Exposures
Financial
GSK Beats Second-Quarter Views, Raises Outlook; But Shares Fall On Shingrix Miss
July 31, 2024
The company, however, raised its sales and earnings outlook for the year.
Via
Investor's Business Daily
Tech Stocks On Track For Best Session In 5 Months Ahead Of Fed Meeting; Small Caps Target Highest Close Since January 2022: What's Driving Markets Wednesday?
July 31, 2024
Tech stocks soared to their best session in five months on Wednesday, ahead of the highly anticipated Federal Open Market Committee (FOMC) meeting.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
GSK Stock Earnings: GSK Beats EPS, Beats Revenue for Q2 2024
July 31, 2024
GSK stock results show that GSK beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Wall Street Remains On Track For AMD-Led Rebound Ahead Of Fed Decision, Meta Earnings: Analyst Says 'The Bull Tends To Remain' Despite Near-Time Volatility
July 31, 2024
Tech optimism is likely to abound on Wall Street as AI-levered stocks are feeding off the strength generated by Advanced Micro Devices, Inc.‘s (NASDAQ:AMD)
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
GSK's Top Selling Vaccine Can Potentially Reduce Dementia Risk, Research Suggests
July 26, 2024
New research suggests that GSK's Shingrix vaccine may reduce dementia risk, potentially revolutionizing treatment for older adults. The study, involving 200,000 people, indicates a significant...
Via
Benzinga
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
July 23, 2024
ViiV Healthcare's Dovato matches Gilead's Biktarvy in effectiveness for HIV treatment. The study reveals Dovato's benefit of less weight gain compared to Biktarvy, highlighting its efficacy and patient...
Via
Benzinga
3 Stocks Under $10 With the Potential for Massive Gains
July 22, 2024
Discover the growth potential of top small-cap stocks in the consumer finance, healthcare equipment and pharmaceutical industries.
Via
InvestorPlace
Top Research Reports For Apple, Lowe's & Shopify
July 17, 2024
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc., Lowe's Companies, Inc., and Shopify Inc., as well as two micro-cap stocks MIND Technology, Inc., and...
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.